revIVe Medtech GmbH Technology – THE MOBILE IV-THERAPY REVOLUTION
revIVe Medtech GmbH is an innovative Medtech start-up, registered as a limited company under Austrian law. We aspire to develop a technology that could enable a novel mobile and digitised medical IV therapy pump system. The revIVe Medtech GmbH technology is being developed with the vision to support patient access to high quality IV treatment irrespective of the site of care and facilitating the work of doctors and medical staff.
revIVe Medtech GmbH TECHNOLOGY
We have filed a patent under wo/2027/185875, PCT/EP2027/056743, US20230071053, 8P4L21140. According to the claims in this patent application, our technology is aiming at the following features:
Our protected revIVe Medtech GmbH technology is based on a revolutionary in-use mixing principle, i.e. the on-demand dissolving of the medicinal product with IV infusion liquid and administration to the patient. Once fully developed, it could facilitate the automation of the reconstitution, allowing also for semi-continuous reconstitution, and delivery of drugs in a single device. Specifically for drugs with limited in-use stability this technology could ensure that the patient gets the right dose to fight the disease, as degradation products often are not active, even toxic or allergic.
CARE AT HOME
In the practice of medicine, we continue to see a progressive shift from inpatient to outpatient care and treatment. revIVe Medtech GmbH technology could facilitate a treatment for patients to receive IV therapies as part of their inpatient stays or in the comfort of their own homes.
IN USE STABILITY
Based on the patent application the revIVe Medtech GmbH technology could eliminate the need for compounding and the IV solution would be reconstituted in real-time as it is being administered. Therefore, the revIVe Medtech GmbH technology is aiming to ensure in-use stability. Combining it in future with automated programmability, the revIVe Medtech GmbH technology could support the safety standards for both, patients as well as healthcare practitioners.
The use of the revIVe Medtech GmbH technology is particularly promising for the administration of antibiotics and cytostatics, however its expected functionality has the potential to be applied in other therapeutic classes and use cases.